株式会社LIFESCAPES

LIFESCAPES operates at the intersection of neurotechnology, medical devices, and rehabilitation, with a focused application: hand and finger rehabilitation for people with severe paralysis after stroke. Its approach links brain-signal detection to robotic movement assistance and electrical stimulation, aiming to make a patient’s neural activity part of the training feedback loop. The company offers both a medical BMI device and a functional-training version for care settings, giving it a use case spanning clinical rehabilitation and facility-based training. This focus distinguishes its stated product scope from broad brain-computer-interface platforms that are not specifically centered on stroke rehabilitation. The company’s stated capabilities include a wearable headset, real-time signal monitoring, and patient-specific training settings; its website also describes a certified Class II medical device. LIFESCAPES is pursuing clinical and commercial development alongside research collaborations, and its June 2026 financing was directed toward physician-led trials and ASEAN expansion. Its competitive differentiation is therefore best assessed by its rehabilitation-specific device design and integration of neural sensing with assisted hand movement.

LIFESCAPES’ development has progressed from research rooted in Keio University’s Ushiba Lab to commercial medical-device development and broader clinical deployment. The company was founded in 2018, and its funding history includes a reported ¥210 million Seed round in November 2020, a ¥720 million round dated June 2022, and an additional ¥200 million Series C round in November 2022. A further ¥600 million round in June 2026, equivalent to approximately $3.75 million in the structured funding record, marked a significant financing step focused on physician-led clinical trials and ASEAN expansion. A ¥50 million JAPANET investment award followed in July 2026. Product activity also points toward widening use: the Functional Training BMI (Finger Type) was introduced at a rehabilitation facility in Aichi in April 2026, while the company continues development of its medical device for severe hand paralysis. The June 2026 appointment of Masaaki Hayashi as president, with founder Junichi Ushiba becoming chairman, represents a leadership transition as the business advances commercialization. NEDO selection in July 2026 added support for its AI-enabled BCI research. Hiring for software engineering and regulatory affairs roles is consistent with the technical and compliance demands of this next phase.